Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Arch Psychiatry Clin Neurosci. 2005 Apr;255(2):149-51. Epub 2004 Nov 19.

Clinical effects of COX-2 inhibitors on cognition in schizophrenia.

Author information

  • 1Hospital for Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität, Nussbaumstr. 7, 80336 München, Germany. norbert.mueller@med.uni-muenchen.de

Abstract

An activation of pro-inflammatory cytokines in the central nervous system is associated with cognitive disturbances. This process is mediated by prostaglandins and cyclo-oxygenase-2 (COX-2). COX-2 inhibitors have been suggested to show beneficial effects in disorders associated with cognitive disturbance, although clinical effects on cognition have not been shown until today. Data from a schizophrenia study were reevaluated under the aspect whether an effect on the positive and negative syndrome scale (PANSS) factor cognition can be observed during therapy with the COX-2 inhibitor celecoxib add on to risperidone in comparison to riperidone alone. Beside the effect on the PANSS total score, the effect on the cognition factor was the most pronounced using the analysis of covariance compared to all other factors of the PANSS (p < 0.06). Although suggestions of basic research led to an expected therapeutic effect of COX-2 inhibitors on cognition, this effect could not yet be shown clinically. In schizophrenia, the effect on cognition contributes to the therapeutic effect of COX-2 inhibitors.

PMID:
15549344
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk